New agents for the management of resistant metastatic breast cancer

Jesus Anampa, Joseph A. Sparano

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Introduction: Metastatic breast cancer (MBC) is an incurable disease and treatment is directed towards symptom palliation and survival prolongation. Treatment selection in patients is based on tumor biology, age, comorbidities, performance status, tumor burden, and prior treatment history. Areas covered: This present review summarizes the recent treatment strategies in the management of MBC, highlighting regimens after first-line therapy. Topics discussed include new strategies for endocrine therapy, anti-HER2 therapy, and promising strategies for the management of triple negative breast cancer. Expert opinion: MBC is a heterogeneous entity and despite recent advances, there is significant room for improvement of treatment beyond first-line therapies. Combination regimens that can maximize clinical efficacy while minimizing toxicities are required. Current investigation approaches in advanced stages of clinical development include immunoconjugates, immune checkpoint blockade, novel cyclin-dependent-kinase inhibitors, and PARP inhibitors for MBC associated with germline BRCA mutations. We recommend that every patient with MBC should be evaluated for clinical trial options.

Original languageEnglish (US)
Pages (from-to)1815-1831
Number of pages17
JournalExpert Opinion on Pharmacotherapy
Issue number17
StatePublished - Nov 22 2017


  • Breast cancer
  • advanced
  • anti-HER2 therapy
  • chemotherapy
  • endocrine therapy
  • metastatic

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'New agents for the management of resistant metastatic breast cancer'. Together they form a unique fingerprint.

Cite this